ALK and non-small cell lung carcinoma: Here, we update the genomic landscape of ALK fusion-driven NSCLC, propose non-canonical ideas to manipulate the partner proteins in ALK fusions, and propose the design of novel immune-epitopes for potential ALK fusion targeted immunotherapy.